News
GCVRZ
0.8711
0.00%
0.0000
FDA experts recommend changes to flu shots
Healthcare FDA experts recommend changes to flu shots for the 2024–2025 season. Group of independent advisers to the FDA voted unanimously to recommend changing the flu vaccines to reflect only the currently circulating viral strains. The move could potentially boost vaccine supplies. The group recommended against adding the vaccine component that targets the B/Yamagata lineage.
Seeking Alpha · 03/07 18:29
Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Apogee Therapeutics' APG777 shows promising Phase 1 results for atopic dermatitis. The antibody has a 75-day half-life, potentially reducing dosing frequency. Apogee is developing a novel antibody targeting IL-13 for the treatment of AD and asthma. The company reported Q4 earnings and pipeline updates today, inspiring a 30%-plus rally in its stock.
Seeking Alpha · 03/05 18:28
‘Tripledemic’ burden lower this winter despite COVID impact: Airfinity
Seeking Alpha · 02/27 18:44
Regeneron, Vertex Pharma join $100B club in biotech
Seeking Alpha · 02/21 12:13
Denali slips as Sanofi fails in mid-stage trial for ALS therapy
Denali Therapeutics shares open lower after Sanofi fails in a mid-stage trial for ALS therapy. The company said its partner Sanofi has faced a setback in a neurology candidate for amyotrophic lateral sclerosis. Sanofi will continue to advance the candidate in another Phase 2 trial for multiple sclerosis.
Seeking Alpha · 02/16 15:05
AstraZeneca tumbles despite Q4 beat
AstraZeneca falls short of analysts' expectations for core operating profits in Q4 2023. The drugmaker's revenue beat forecasts as its oncology portfolio outperformed. AstraZeneca lost as much as 6% in London trading Thursday after reporting Q4 results.
Seeking Alpha · 02/08 12:09
Regeneron posts Q4 beat even as Eylea, COVID-19 sales dip
Regeneron posts Q4 beat even as Eylea, COVID-19 sales dip. Regeneron Pharma topped Wall Street forecasts with its Q4 2023 financials. The company posted $3.43B in revenue for the quarter. Sales from its blockbuster eye disease therapy, EyleA, and COVID 19 therapy, Regen-Cov, dropped.
Seeking Alpha · 02/02 12:13
Sanofi proposes annual dividend of €3.76
Seeking Alpha · 02/01 12:55
Sanofi Non-GAAP EPS of €1.66, revenue of €10.92B; initiates FY24 outlook
Sanofi initiates its FY24 outlook and reported Q4 results. Q4 Non-GAAP EPS of €1.66, revenue of €10.92B; initiates FY24 Outlook of 9.3% sales growth at CER. Vaccines sales increased strongly with Beyfortus uptake.
Seeking Alpha · 02/01 06:38
Teva hits 52-week high on outlook, API divestment
generic drugmaker Teva Pharmaceutical hits 52-week high on outlook, API divestment. Teva's 2024 revenue outlook ahead of consensus and announced plans to divest its active-pharmaceutical ingredient business. The company's Q4 2023 revenue jumped 15% YoY to $4.5B.
Seeking Alpha · 01/31 16:34
Regeneron/ Sanofi win label expansion for Dupixent in esophageal disorder
Regeneron/ Sanofi win label expansion for Dupixent in esophageal disorder. FDA expanded the labeling for use in children aged 1–11 years with eosinophilic esophagitis. The immune-mediated disease primarily affects the esophagus.
Seeking Alpha · 01/25 19:56
Masking returns to some U.S. hospitals amid rising COVID, flu cases
Healthcare Masking returns to some U.S. Hospitals amid rising COVID, flu cases amid rising temperatures. New York, California, Illinois, and Massachusetts hospitals have reimposed masking requirements for patients and staff. The decision comes amid a spike in COVID and flu infections.
Seeking Alpha · 01/04 18:51
Biden administration secures 230K more RSV injections for infants
Healthcare Biden administration secures 230K more RSV injections for infants in January. An additional 230K doses of RSV immunizations will be made available for infants. RSV is a leading cause of respiratory infections in infants. Sanofi and AstraZeneca are among the drugmakers involved in the agreement.
Seeking Alpha · 12/14/2023 20:46
Pneumonia outbreak in China is no reason for alarm: WHO
Healthcare pneumonia outbreak in china is no reason for alarm: who. World health organization advised against imposing travel restrictions after outbreak of respiratory illnesses in china. Outbreak sparked fears of a novel pathogen similar to the covid-19 pandemic four years ago. Who says there were no detections of novel pathogens or unusual clinical presentations.
Seeking Alpha · 11/24/2023 17:35
M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey
Healthcare executives expect a rebound in healthcare m&a activity in 2024 as covid-19 fades. Jefferies survey says glp-1 class of weight loss drugs will dominate major healthcare themes in 2024. Ipos and spac-driven deals will dominate the healthcare sector in 2024, according to the survey.
Seeking Alpha · 11/19/2023 17:00
Madrigal adds former Sanofi executive as commercial chief
Madrigal pharmaceuticals adds former sanofi executive as commercial chief. Carole huntsman most recently served as u.s. Country lead of the french pharma giant. Madrigal is preparing to launch liver disease drug resmetirom in the united states in 2024.
Seeking Alpha · 11/10/2023 13:18
UnitedHealth to prefer eight insulin products to cut out-of-pocket costs
Unitedhealth to prefer eight insulin products to cut out-of-pocket costs. The move will expand the number of patients paying $35 or less monthly for insulin to 98% from 70%, the company says. Eli lilly, novo nordisk and sanofi insulin products will be moved to "preferred" status on formularies.
Seeking Alpha · 11/09/2023 19:02
Sanofi said to be under scrutiny over possible market manipulation
Seeking Alpha · 11/07/2023 12:30
Regeneron raised to Outperform at Raymond James on Q3 results
Seeking Alpha · 11/03/2023 12:40
Amicus Therapeutics: The Right Play Now
Seeking Alpha · 10/31/2023 16:24
More
Webull provides a variety of real-time GCVRZ stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About GCVRZ
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.